Furthermore, NR4A1 interacts, and blocks binds and sequesters Liver kinase B1 (LKB1) in the nucleus, then releases and shuttles LKB1 to the cytoplasm, thereby attenuating AMP-activated protein kinase (AMPK) activation to treat metabolic diseases such as streptozotocin-induced diabetes (37). The gene discussed is STK11; the disease is metabolic disease.